Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2012. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director share allocations rather than corporate financial performance.
Material Changes
On March 30, 2012, Non-Executive Directors were allocated notional Ordinary Shares at a price of £14.07 per share and notional American Depositary Shares (ADSs) at a price of $45.10 per ADS. These allocations covered the service period from January 1, 2012, to March 31, 2012. The Company and Directors were informed of these allocations on April 2, 2012.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Non-Executive Directors received notional share allocations for Q1 2012 service.
- Allocation price was £14.07 per Ordinary Share and $45.10 per ADS.
- Specific allocation quantities were assigned to individual directors including Sir Christopher Gent, Professor Sir Roy Anderson, and others.
- This filing contains no operational or financial performance data for the company.